Biosimilar developer Sandoz announced today that it has entered into a global partnership with India-based Biocon to develop, manufacture, and commercialize multiple biosimilars targeting immunology and oncology indications.
Biosimilar developer Sandoz announced today that it has entered into a global partnership with India-based Biocon to develop, manufacture, and commercialize multiple biosimilars targeting immunology and oncology indications.
Under the agreement, the companies will share responsibility for end-to-end development, manufacturing, and regulatory approvals for the products in question, and will share costs and profits. Sandoz will lead commercialization of approved biosimilars in North America and the European Union, while Biocon will commercialize the drugs in the rest of the world.
“Today’s announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future,” said Richard Francis, CEO of Sandoz, in a statement. “Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics.”
Chairperson and managing director of Biocon, Kiran Mazumdar-Shaw, added, “This synergistic partnership will enable us to scale up our capabilities for an end-to-end play in the global biosimilars space.”
The agreement with Sandoz forms Biocon’s second partnership seeking to bring its biosimilars to the US and EU markets; Biocon successfully partnered with Mylan on a trastuzumab biosimilar, Ogivri, approved by the FDA in December 2017. Last week, at the 36th Annual J.P. Morgan Healthcare Conference, Rajiv Malik, company president of Mylan, hinted that Biocon—Mylan’s pegfilgrastim biosimilar could gain FDA approval by the middle of 2018. Both the trastuzumab and pegfilgrastim products are also under European regulatory review.
News of the Sandoz—Biocon partnership comes just days after Sandoz announced that the FDA has accepted for review its Biologics License Application (BLA) for a proposed adalimumab (Humira) biosimilar. The drug maker has already received FDA’s nod for its etanercept biosimilar (which will be marketed in the United States as Erelzi, though no launch date has been made public) and its filgrastim biosimilar (Zarxio). The FDA is currently considering a BLA for Sandoz’s rituximab biosimilar, and the drug maker reports that it will refile its BLA for a pegfilgrastim biosimilar in 2019.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.